Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI-Identified Themes From Early Comment Analysis Avoid Pharma Industry Concerns

Executive Summary

The Patient-Centered Outcomes Research Institute identifies themes from early analysis of comments received on its Methodology Committee report, but it is not clear whether these themes address concerns raised by the pharmaceutical industry.

You may also be interested in...



PCORI Critics Emerge As Institute Formally Releases Draft Methods Report

As the Patient-Centered Outcomes Research Institute opens the public comment period for its draft methodology report, criticisms on the institute's direction are beginning to surface, including accusations that it is becoming just another AHRQ or NIH.

PCORI Following Intent Of Legislators, But Needs To Be Careful In Defining “Patient-Centered Outcomes Research” – Former Senate Staffer

A former member of the Senate Finance Committee staff that contributed to the writing of the health care reform law that formed the Patient-Centered Outcomes Research Institute believes the institute is following the intent laid out by the committee, but has concerns on the current draft definition.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel